AIM ImmunoTech Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
AIM ImmunoTech Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2017 to Q4 2023.
  • AIM ImmunoTech Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2023 was $1.18M, a 29.4% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $1.18M -$492K -29.4% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 $48K Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $33K Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.76M Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $1.68M Dec 31, 2022 10-K 2024-04-01
Q3 2021 $28K +$2K +7.69% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $28K -$18K -39.1% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $34K -$12K -26.1% Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $34K -$10K -22.7% Dec 31, 2020 10-K 2022-03-31
Q3 2020 $26K -$36K -58.1% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $46K -$30K -39.5% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $46K -$55K -54.5% Mar 31, 2020 10-Q/A 2020-05-14
Q4 2019 $44K -$191K -81.3% Dec 31, 2019 10-K 2021-03-31
Q3 2019 $62K +$34K +121% Sep 30, 2019 10-Q 2019-11-14
Q2 2019 $76K +$41K +117% Jun 30, 2019 10-Q 2019-08-14
Q1 2019 $101K +$72K +248% Mar 31, 2019 10-Q 2019-05-15
Q4 2018 $235K +$211K +879% Dec 31, 2018 10-K 2020-03-30
Q3 2018 $28K -$14K -33.3% Sep 30, 2018 10-Q 2018-11-14
Q2 2018 $35K -$63K -64.3% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 $29K -$12K -29.3% Mar 31, 2018 10-Q 2018-05-15
Q4 2017 $24K Dec 31, 2017 10-K 2019-04-01
Q3 2017 $42K Sep 30, 2017 10-Q 2017-11-14
Q2 2017 $98K Jun 30, 2017 10-Q 2017-08-14
Q1 2017 $41K Mar 31, 2017 10-Q 2017-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.